Industry leaders agree that multiplex array technologies are a key to realizing the therapeutic potential of genomic data. While pioneering companies like Affymetrix offer high-quality product lines, companies with creative technologies--such as Nanogen and Gene Logic--are making gains by offering flexible products for specialized applications such as single nucleotide polymorphism analysis, diagnostics, and high-throughput screening. In addition, emerging technologies such as protein chips and bead-based arrays promise to extend the range and potential of hybridization arrays. This report reviews dozens of companies offering DNA array technology (and related technologies, such as protein chips and microfluidic chips), reviews business issues and challenges, and looks at the strategies of industry leaders.
Targeting both business and technical professionals, this report:
- --Evaluates the forces driving demand for DNA arrays and comprehensively reviews the state of this technology area.
- --Reviews the business challenges and technical hurdles facing the maturation of the field.
- --Provides a market forecast through 2006 and discusses trends in DNA-related dealmaking, based on information from CHI's Drug Discovery and Development Deals Database.
- --Provides 23 in-depth company profiles and more than 50 brief profiles.
Thought Leaders Interviewed for This Report
Michael Boyce-Jacino, Orchid BioSciences; Michael Brennan, formerly of Gene Logic; David Craford, Affymetrix; Stephen Friend, Rosetta Inpharmatics; Michael J. Heller, Nanogen; Michael R. Knapp, Caliper Technologies; Michael N. Liebman, Genmatics; Gavin MacBeath, Harvard Center for Genomics Research; Antonio J. Ricco and Maureen Cronin, ACLARA BioSciences; Stanley D. Rose, Affymetrix
View Cart
